Bioventus Q2 revenue up 10.3% (organic +13.9%); raises FY2024 guidance

Bioventus Inc.

2024-Q2 EPS reported -$0.45 revenue$280,674,000

Revenue $151.2M (+10.3% YoY); Pain Treatments +17.2%, Surgical Solutions +18.6% US.
Net loss from continuing operations $32.1M vs $4.7M, including $31.9M impairment and litigation settlement.
Adjusted EBITDA $34.5M (+22.4% YoY); non-GAAP EPS $0.19 vs $0.14.
Raising FY2024 guidance: revenue $557-567M, adjusted EBITDA $104-107M, non-GAAP EPS $0.36-0.42.
FDA clearance for OSTEOAMP Cannula; pursuing divestiture of Advanced Rehabilitation to reduce debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.